Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

1. Infection prevention and control

Infection prevention and control Guidelines Infection prevention and control 2020 January 20202 Association of Anaesthetists | Infection prevention and control 2020 Infection prevention and control 2020 Membership of the working party C.R. Bailey, 1 B. Greatorex, 2 Y. Hyde, 3 R. Koerner, 4 N. McGuire, 5 T. Meek 6 and S. Radhakrishna 7 1 Consultant, Department of Anaesthetics, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; Chair of Working Party, Association of Anaesthetists 2 Specialist (...) Trainee, Department of Anaesthetics, John Radcliffe Hospital, Oxford, UK; Association of Anaesthetists Trainee Committee 3 Senior Infection Prevention and Control Nurse, Cardiff and Vale University Health Board, Cardiff, UK 4 Consultant, Department of Microbiology, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK 5 Clinical Director of Medical Devices, Medicines and Healthcare products Regulatory Agency 6 Consultant, Department of Anaesthetics, South Tees Hospitals NHS Foundation Trust

2020 Association of Anaesthetists of GB and Ireland

2. Plus Sutures for preventing surgical site infection

Plus Sutures for preventing surgical site infection Plus Sutures for preventing surgical site infection Medtech innovation briefing Published: 4 February 2020 www.nice.org.uk/guidance/mib204 pathways Summary Summary The technology technology described in this briefing is Plus Sutures. It is for wound closure in adults and children after surgical procedures. The innovative aspect innovative aspect is that the sutures contain the antimicrobial substance triclosan. The intended place in therapy (...) place in therapy would be as an alternative to standard care for people who need wound closure after a surgical procedure. The main points from the evidence main points from the evidence summarised in this briefing are from 7 studies, including 3 meta-analyses, 1 systematic review and 3 randomised controlled trials including adults and children in a secondary care setting. Most studies found Plus Sutures more effective than standard care sutures in reducing surgical site infections. Key

2020 National Institute for Health and Clinical Excellence - Advice

3. Leg ulcer infection: antimicrobial prescribing

Leg ulcer infection: antimicrobial prescribing Leg ulcer infection: antimicrobial prescribing NICE guideline Published: 11 February 2020 www.nice.org.uk/guidance/ng152 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Leg ulcer infection: antimicrobial prescribing (NG152) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Managing leg ulcer

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

4. Is IV iron safe to give in patients with active infection?

Is IV iron safe to give in patients with active infection? Chiefs’ Inquiry Corner – 1/27/20 – Clinical Correlations Search Chiefs’ Inquiry Corner – 1/27/20 January 27, 2020 2 min read The iron-infection hypothesis postulates that because bacteria need iron to survive and replicate, our bodies have evolved to respond to infections by sequestering iron intracellularly away from the extracellular bacteria. Although the most recent, large meta-analysis suggests routine use of IV iron (...) was not associated with an increased risk of infections, is there any data on the safety of giving IV iron to patients who are actively infected? Sadly, there is no good data for humans (only animal studies). So, as always, weigh the risks and benefits each time. References: It is an established phenomenon that patients with well-controlled HIV can see a tremendous drop in their CD4 count during acute illness. This effect can also be seen in critically ill patients even without HIV. This drop is transient

2020 Clinical Correlations

5. Clostridioides difficile Infection in Adults and Children

Clostridioides difficile Infection in Adults and Children Quality Department Guidelines for Clinical Care 1 UMHS C. difficile Infection in Adults and Children 12/2019 Clostridioides difficile Infection Guideline Team Team Leads Tejal N Gandhi MD Infectious Diseases Krishna Rao, MD Infectious Diseases Team Members Gregory Eschenauer, PharmD Pharmacy John Y Kao, MD Gastroenterology Lena M Napolitano, MD Surgery F Jacob Seagull, PhD Leaning Heath Sciences David M Somand, MD Emergency Medicine (...) Alison C Tribble, MD Pediatric Infectious Diseases Amanda M Valyko, MPH, CIC Infection Control Michael E Watson Jr, MD, PhD Pediatric Infectious Diseases Consultants: Meghan A. Arnold, MD Pediatric Surgery Laraine Lynn Washer, MD Infection Diseases Initial Release: December 2016 Most Recent Major Update December 2019 Inpatient Clinical Guidelines Oversight Megan R Mack, MD David H Wesorick, MD F Jacob Seagull, PhD Literature search service Taubman Health Sciences Library For more information: 734

2020 University of Michigan Health System

6. Clinical Practice Guideline on the Diagnosis and Prevention of Periprosthetic Joint Infections

Clinical Practice Guideline on the Diagnosis and Prevention of Periprosthetic Joint Infections 1 View the background material via the PJI CPG eAppendix 1 View data summaries via the PJI CPG eAppendix 2 DIAGNOSIS AND PREVENTION OF PERIPROSTHETIC JOINT INFECTIONS CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors March 11, 2019 Endorsed by: Please cite this guideline as: American Academy of Orthopaedic Surgeons. Diagnosis and Prevention (...) of Periprosthetic Joint Infections Clinical Practice Guideline. https://www.aaos.org/pjiguideline. Published March 11, 2019.2 View the background material via the PJI CPG eAppendix 1 View data summaries via the PJI CPG eAppendix 2 Disclaimer This clinical practice guideline was developed by a physician volunteer clinical practice guideline development group based on a formal systematic review of the available scientific evidence and accepted approaches to care. This clinical practice guideline is not intended

2020 American Academy of Orthopaedic Surgeons

7. Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group

Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group Predictive Factors of Severe Infections in Patients With Systemic Necrotizing Vasculitides: Data From 733 Patients Enrolled in Five Randomized Controlled Trials of the French Vasculitis Study Group - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) Cancel Add to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions 2019 Nov 28 [Online ahead of print] Predictive Factors of Severe Infections in Patients With Systemic

2020 EvidenceUpdates

8. Diabetic Foot Infections

Diabetic Foot Infections Quality Department Guidelines for Clinical Care Inpatient 1 UMHS Diabetic Foot Infection 10/2019 Diabetic Foot Infection Guideline Team Team Leaders John P. Mills, MD Infectious Disease Payal Patel, MD Infectious Disease Team Members Stephanie Burdick, MD Internal Medicine Christina DeGeorge, PA-C Endocrinology Katherine A. Gallagher, MD Vascular Surgery Crystal M. Holmes, DPM Podiatry Jon A. Jacobson, MD Radiology Jerod L. Nagel, PharmD Pharmacy F. Jacob Seagull, PhD (...) information: 734-936-9771 © Regents of the University of Michigan These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Diabetic Foot Infections Patient population: Adult diabetic patients. Objectives: Improve quality

2020 University of Michigan Health System

9. Gastrointestinal infections: guidance for public health management

Gastrointestinal infections: guidance for public health management Gastrointestinal infections: guidance for public health management - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search The UK has left the EU Guidance Gastrointestinal infections: guidance for public health management (...) Guidance to help professionals in public health and environmental health departments to minimise the risk of transmission of gastrointestinal infections. Published 31 January 2020 From: Documents Ref: PHE publications gateway number: GW-1020 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This guidance

2020 Public Health England

10. European surveillance of Clostridioides (Clostridium) difficile infections - surveillance protocol version 2.4

European surveillance of Clostridioides (Clostridium) difficile infections - surveillance protocol version 2.4 TECHNICAL DOCUMENT European Surveillance of Clostridioides (Clostridium) difficile infections Surveillance protocol version 2.4 2019 www.ecdc.europa.euECDC TECHNICAL DOCUMENT European surveillance of Clostridioides (Clostridium) difficile infections Surveillance protocol version 2.4 ii This technical document is an update of ‘European Surveillance of Clostridium difficile infections (...) . with consortium members from the ECDC project ‘ECDIS-Net’ (2009—2013) and ‘ECDIS-Net-2’ (2013—2015); and presentation of the initial protocol to the ECDC Advisory Forum prior to publication. Annex 3 contains a list of relevant publication dates; ECDC meetings; and all consulted experts, to whom ECDC is extremely grateful. The current protocol (version 2.4) was prepared by Pete Kinross and Carl Suetens. Addition of optional variables to record structure and process indicators of infection prevention

2020 European Centre for Disease Prevention and Control - Technical Guidance

11. 2019 EHRA International Consensus Document on How to Prevent, Diagnose, and Treat Cardiac Implantable Electronic Device Infections

2019 EHRA International Consensus Document on How to Prevent, Diagnose, and Treat Cardiac Implantable Electronic Device Infections 2019 EHRA International Consensus Document on How to Prevent, Diagnose, and Treat Cardiac Implantable Electronic Device Infections | Heart Rhythm Society Utility Menu Main navigation Search Main Menu Breadcrumb Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy devices are life-saving treatments for a number of cardiac conditions (...) . Device-related infection is, however, one of the most serious complications of cardiac implantable electronic device (CIED) therapy associated with significant morbidity, mortality, and financial health care burden. Although many preventive strategies such as administration of intravenous antibiotic therapy before implantation are well recognized, uncertainties still exist about other regimens. Questions still remain such as the use of CIED alternatives expected to be less prone to infections and how

2020 Heart Rhythm Society

12. COVID-19: infection prevention and control

COVID-19: infection prevention and control Wuhan novel coronavirus: infection prevention and control - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Wuhan novel coronavirus: infection prevention and control Guidance on infection prevention and control for Wuhan novel (...) coronavirus. Published 10 January 2020 Last updated 15 January 2020 — From: Documents HTML Details This guidance outlines infection control for healthcare providers assessing possible cases of WN-CoV. It should be used in conjunction with local policies. In the absence of effective drugs or a vaccine, control of this virus relies on the prompt identification, appropriate risk assessment, management and isolation of possible and confirmed cases, and the investigation and follow up of close contacts

2020 Public Health England

13. Investigations before starting treatment for late-onset neonatal infection in babies

Investigations before starting treatment for late-onset neonatal infection in babies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

14. Healthcare worker experiences of implementing tuberculosis (TB) infection control in high TB burden countries: a thematic synthesis

Healthcare worker experiences of implementing tuberculosis (TB) infection control in high TB burden countries: a thematic synthesis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2020 PROSPERO

15. Analysis of emergency department prediction tools in evaluating febrile young infants at risk for serious infections

Analysis of emergency department prediction tools in evaluating febrile young infants at risk for serious infections Analysis of Emergency Department Prediction Tools in Evaluating Febrile Young Infants at Risk for Serious Infections - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable (...) your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Emerg Med J Actions , 36 (12), 729-735 Dec 2019 Analysis of Emergency Department Prediction Tools in Evaluating Febrile Young Infants at Risk for Serious Infections , , , , Affiliations Expand Affiliations 1 Department of Emergency Medicine, KK Women's and Children's Hospital, Singapore, Singapore. 2 Faculty

2020 EvidenceUpdates

16. Prognostic accuracy of qSOFA in predicting 28-day mortality among infected patients in an emergency department: a prospective validation study Full Text available with Trip Pro

Prognostic accuracy of qSOFA in predicting 28-day mortality among infected patients in an emergency department: a prospective validation study Prognostic Accuracy of qSOFA in Predicting 28-day Mortality Among Infected Patients in an Emergency Department: A Prospective Validation Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several (...) than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Emerg Med J Actions , 36 (12), 722-728 Dec 2019 Prognostic Accuracy of qSOFA in Predicting 28-day Mortality Among Infected Patients in an Emergency Department: A Prospective Validation Study , , , , , Affiliations Expand Affiliations 1 Department

2020 EvidenceUpdates

17. Infants born to hepatitis B-infected mothers: immunoglobulin policy

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

2020 Public Health England

18. The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP

The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP | The Ontario HIV Treatment Network The Ontario HIV Treatment Network The risk of HIV among women after acquiring a sexually transmitted infection (STI) and considerations for their use of PrEP The risk of HIV among women after acquiring a sexually (...) transmitted infection (STI) and considerations for their use of PrEP , , , , , , Questions What is the current evidence among women in high-income countries regarding HIV risk after acquiring a sexually transmitted infection (STI)? What does the evidence state regarding the use of pre-exposure prophylaxis (PrEP) to prevent HIV among women who have acquired an STI? Key take-home messages A recent study in the U.S. found that most women who were diagnosed with HIV did not have a reported STI in the past (1

2020 Ontario HIV Treatment Network

19. Cefiderocol (Fetroja) - urinary tract infections

Cefiderocol (Fetroja) - urinary tract infections Drug Approval Package: FETROJA (cefiderocol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: FETROJA (cefiderocol) Company: Shionogi, Inc. Application Number: 209445Orig1s000 Approval Date: 11/14/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

20. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study Full Text available with Trip Pro

Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study Overall Infection Risk in Rheumatoid Arthritis During Treatment With Abatacept, Rituximab and Tocilizumab; An Observational Cohort Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Rheumatology (Oxford) Actions 2019 Nov 25 [Online ahead of print] Overall Infection Risk in Rheumatoid Arthritis During Treatment With Abatacept, Rituximab and Tocilizumab; An Observational Cohort Study , , , , , , , Affiliations Expand Affiliations 1 DANBIO and Copenhagen

2020 EvidenceUpdates